PIPELINE
Our programs
The Volastra pipeline has multiple programs targeting the unique biology of chromosomally unstable cancer cells. Complementing these programs are our innovative biomarker approaches designed to pair each therapy with the patients who will benefit the most.
Program
Tumor
Target
Pre Clinical
Phase 1
Phase 2/3
Rights
Tumor
Target
Pre Clinical
Phase 1
Phase 2/3
Ovarian & Solid tumors
KIF18A
KIF18A
Ovarian & Solid tumors
VLS-1488
Rights:
VLS-1488 is a differentiated oral small molecule KIF18A inhibitor currently being studied in a Phase 1 clinical trial (NCT05902988) for advanced solid tumors known to have high levels of chromosomal instability. VLS-1488 has received fast track designation in platinum-resistant high grade serous ovarian cancer.
LEARN MORETumor
Target
Pre Clinical
Phase 1
Phase 2/3
Ovarian
KIF18A
KIF18A
Ovarian
Sovilnesib
Rights:
Sovilnesib (previously AMG650) is a differentiated oral small molecule KIF18A inhibitor being developed in ovarian cancer. It recently completed a Phase 1 clinical trial and a Phase 1b trial was initiated in early 2024 (NCT06084416). Sovilnesib has received fast track designation in platinum-resistant high grade serous ovarian cancer.
LEARN MORETumor
Target
Pre Clinical
Phase 1
Phase 2/3
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Program 3
Rights:
Tumor
Target
Pre Clinical
Phase 1
Phase 2/3
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Program 4
Rights:
Tumor
Target
Pre Clinical
Phase 1
Phase 2/3
Additional Targets in discovery
Additional Targets in discovery
CINsight Engine